Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-Bromoindirubin-3'-acetoxime (BiA) is a synthetic small molecule derivative of indirubin, a natural compound found in indigo plants and the Mediterranean mollusk *Hexaplex trunculus*. It acts as a potent, ATP-competitive protein kinase inhibitor with a broad selectivity profile, primarily targeting glycogen synthase kinase-3 (GSK-3), Src-family kinases, and JAK2. BiA has been investigated for its therapeutic potential in oncology, particularly for glioblastoma (GBM) and pediatric diffuse midline glioma (DMG), where it has shown the ability to modulate the blood-brain barrier, inhibit tumor cell migration, and exert anti-angiogenic effects. Additionally, the compound has demonstrated antiviral activity against herpes simplex virus-1 (HSV-1) and varicella zoster virus. To address its poor solubility and bioavailability, a nanoparticle formulation known as PPRX-1701 was developed by Phosphorex, which has shown preclinical efficacy in brain tumor models by downregulating immunosuppressive pathways such as IDO1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-bromoindirubin-3'-acetoxime.